|
全民健康保險藥品給付規定 / 健保碼及健保價 |
|
See related Enbrel[恩博] information |
|
|
|
製造商 |
Pfizer |
|
代理/經銷商 |
Pfizer |
|
成份 |
Etanercept |
|
適應症 |
Treatment of active RA in adults when the response to disease-modifying antirheumatic drugs, including methotrexate has been inadequate. Treatment of severe, active & progressive RA in adults not previously treated with methotrexate. Treatment of active polyarticular-course juvenile chronic arthritis in children 4-17 years who have had an inadequate response to, or who are intolerant of, methotrexate. Treatment of active & progressive psoriatic arthritis in adults when the response to DMARD therapy has been inadequate. Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. Treatment of adults with moderate to severe plaque psoriasis who failed to respond to, or have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or PUVA.Treatment of active polyarticular juvenile idiopathic arthritis in adolescents & childn ≥4 yr w/ inadequate response or intolerant to methotrexate. Treatment of chronic severe plaque psoriasis in adolescents & childn ≥8 yr inadequately controlled by or intolerant to other systemic therapies or phototherapies. |
|
用量 |
SC Adult (18-64 years) RA 25 mg twice weekly or 50 mg once weekly. Psoriatic arthritis & ankylosing spondylitis 25 mg twice weekly or 50 mg once weekly. Plaque psoriasis Initially 25 mg twice weekly or 50 mg twice weekly for up to 12 weeks, then reduce to 25 mg twice weekly. Treatment should continue until remission is achieved, for up to 24 weeks; discontinue if no response after 12 weeks. Children ≥ 4 years Juvenile idiopathic arthritis 0.4 mg/kg (max: 25 mg/dose) twice weekly at 3-4 day intervals. Children ≥ 8 years Pediatric plaque psoriasis 0.8 mg/kg (max: 50 mg/dose) weekly for up to 24 weeks |
|
美國食品藥物管理局之懷孕等級 |
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters). |
|
禁忌 |
Sepsis or risk of sepsis; active infections including chronic or localized infections. |
|
注意事項 |
History of recurring or chronic infections or conditions which may predispose patient to infections. Concurrent administration of anakinra & live vaccines. History of blood dyscrasias; pre-existing or recent-onset CNS demyelinating disease, or those at risk of developing demyelinating disease; CHF. Pregnancy, lactation. |
|
不良反應 |
Inj site reactions, infections, allergic reactions, autoantibody formation, pruritus, fever. Rarely, serious infections including sepsis, CNS demyelinating disorders, worsening of CHF, pancytopenia (& very rarely aplastic anaemia).
View ADR Monitoring Website[參閱藥物不良反應監測表格] |
|
交互作用 |
Avoid concomitant use with anakinra. Avoid concurrent use with live vaccines.
View more drug interactions with Enbrel[恩博] |
|
本商品之市售規格 |
|
劑型 |
包裝 |
圖片 |
|
Enbrel 凍晶注射劑 |
|
|
Enbrel 注射劑 |
|
|
|
Manufacturer: |
Pfizer |
|
Distributor: |
Pfizer |
|
|
|
|
|
